Mirjam Renovanz1, Larissa Reitzug2, Linda Messing2, Armin Scheurich3, Sonja Grüninger4, Florian Ringel2, Jan Coburger4. 1. Department of Neurosurgery, University Medical Centre, Johannes-Gutenberg-University Mainz, 55131 Mainz, Germany. Electronic address: mirjam.renovanz@unimedizin-mainz.de. 2. Department of Neurosurgery, University Medical Centre, Johannes-Gutenberg-University Mainz, 55131 Mainz, Germany. 3. Department of Psychiatry and Psychotherapy, University Medical Centre, Johannes-Gutenberg-University Mainz, 55131 Mainz, Germany. 4. Department of Neurosurgery, University Medical Centre Ulm/Günzburg, 89312 Günzburg, Germany.
Abstract
BACKGROUND: Montreal Cognitive Assessment (MoCA) represents a short screening tool for neuropsychological deficits. The study's aim was to test feasibility and acceptance of MoCA in patients with brain tumours perioperatively. METHODS: Patients with supratentorial located brain tumours were assessed preoperatively (t1, day -1) and postoperatively (t2, day 3-5) using EORTC-QLQ-C30 + BN20, Distress Thermometer (DT) and the MoCA test (different versions). Feasibility was evaluated by a feedback form and patients were asked about perceived discomfort, overstraining or complexity of MoCA. Results of MoCA were correlated with clinical factors. RESULTS: 63 patients participated, 19 were male. Mean age was 56 years. Mean completion time of MoCA was 11 min (both t1 and t2). At t1, in 27% "moderate or major difficulties" occurred during MoCA assessment vs. 41% at t2. Most of the patients (t1, 93% vs. t2, 86%) negated to be overstrained by MoCA. Better "physical function" according to EORTC-QLQ-C30 (p = 0.041, Pearson = 0.321) and higher KPS (p = 0.012, Pearson = 0.578) correlated to higher MoCA scores. Higher distress at t2 was found to be correlated with a stronger deterioration of MoCA at t2 vs. t1 (p = 0.03, Spearman-Rho = .695). CONCLUSION: The MoCA test was well accepted by the patients and implementable in clinical routine. Further investigations evaluating the sensitivity and specificity of the test in brain tumour patients are required.
BACKGROUND: Montreal Cognitive Assessment (MoCA) represents a short screening tool for neuropsychological deficits. The study's aim was to test feasibility and acceptance of MoCA in patients with brain tumours perioperatively. METHODS:Patients with supratentorial located brain tumours were assessed preoperatively (t1, day -1) and postoperatively (t2, day 3-5) using EORTC-QLQ-C30 + BN20, Distress Thermometer (DT) and the MoCA test (different versions). Feasibility was evaluated by a feedback form and patients were asked about perceived discomfort, overstraining or complexity of MoCA. Results of MoCA were correlated with clinical factors. RESULTS: 63 patients participated, 19 were male. Mean age was 56 years. Mean completion time of MoCA was 11 min (both t1 and t2). At t1, in 27% "moderate or major difficulties" occurred during MoCA assessment vs. 41% at t2. Most of the patients (t1, 93% vs. t2, 86%) negated to be overstrained by MoCA. Better "physical function" according to EORTC-QLQ-C30 (p = 0.041, Pearson = 0.321) and higher KPS (p = 0.012, Pearson = 0.578) correlated to higher MoCA scores. Higher distress at t2 was found to be correlated with a stronger deterioration of MoCA at t2 vs. t1 (p = 0.03, Spearman-Rho = .695). CONCLUSION: The MoCA test was well accepted by the patients and implementable in clinical routine. Further investigations evaluating the sensitivity and specificity of the test in brain tumourpatients are required.
Authors: Varna Jammula; James L Rogers; Elizabeth Vera; Alexa Christ; Heather E Leeper; Alvina Acquaye; Nicole Briceno; Anna Choi; Ewa Grajkowska; Jason E Levine; Matthew Lindsley; Jennifer Reyes; Kayla N Roche; Michael Timmer; Lisa Boris; Eric Burton; Nicole Lollo; Marissa Panzer; Matthew A Smith-Cohn; Marta Penas-Prado; Valentina Pillai; Brett J Theeler; Jing Wu; Mark R Gilbert; Terri S Armstrong Journal: Neurooncol Pract Date: 2022-05-14
Authors: Annika Malmström; Lisa Åkesson; Peter Milos; Munila Mudaisi; Helena Bruhn; Michael Strandeus; Marit Karlsson Journal: Support Care Cancer Date: 2020-10-30 Impact factor: 3.603